[go: up one dir, main page]

DE602004029812D1 - Fgf-5-bindende und geträgerte peptide - Google Patents

Fgf-5-bindende und geträgerte peptide

Info

Publication number
DE602004029812D1
DE602004029812D1 DE602004029812T DE602004029812T DE602004029812D1 DE 602004029812 D1 DE602004029812 D1 DE 602004029812D1 DE 602004029812 T DE602004029812 T DE 602004029812T DE 602004029812 T DE602004029812 T DE 602004029812T DE 602004029812 D1 DE602004029812 D1 DE 602004029812D1
Authority
DE
Germany
Prior art keywords
peptides
preferred embodiments
fgf
binding
particularly preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029812T
Other languages
English (en)
Inventor
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Beverly R Turnquest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Publication of DE602004029812D1 publication Critical patent/DE602004029812D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
DE602004029812T 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide Expired - Lifetime DE602004029812D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53120703P 2003-12-19 2003-12-19
US53118903P 2003-12-19 2003-12-19
US53095403P 2003-12-19 2003-12-19
PCT/US2004/036980 WO2005047314A2 (en) 2003-11-06 2004-11-06 Fgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
DE602004029812D1 true DE602004029812D1 (de) 2010-12-09

Family

ID=34596198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004029812T Expired - Lifetime DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide
DE602004029393T Expired - Lifetime DE602004029393D1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004029393T Expired - Lifetime DE602004029393D1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1680507B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE482972T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029812D1 (de)
DK (2) DK1680507T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005047314A2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292641B1 (de) * 2003-11-06 2017-12-06 Danisco US Inc. Expression in faserigen Pilzen von Proteasehemmern und Varianten davon
DE602004029812D1 (de) * 2003-11-06 2010-12-09 Danisco Us Inc Fgf-5-bindende und geträgerte peptide
JP5255841B2 (ja) * 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
CN101278051B (zh) * 2005-05-05 2011-10-05 金克克国际有限公司 个人护理组合物及其使用方法
ATE477272T1 (de) 2005-06-10 2010-08-15 Medical Res Council Verwendung von stefin a als gerüstprotein
KR20080042070A (ko) * 2005-07-13 2008-05-14 암젠 마운틴 뷰 인코포레이티드 Ｉｌ-6 결합 단백질
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
EP2061313B1 (de) * 2006-09-16 2013-06-19 SOY Labs LLC Verwendung von sojapeptid (lunasin) zur senkung des gesamt- und des ldl-cholesterinspiegels
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
US8282688B2 (en) * 2006-12-18 2012-10-09 Danisco Us Inc. Laccase mediators and methods of use
JP2010512787A (ja) 2006-12-21 2010-04-30 ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン バシルス（Ｂａｃｉｌｌｕｓ）種１９５のアルファ‐アミラーゼポリペプチドの組成物と使用。
US9133425B2 (en) * 2007-06-06 2015-09-15 Danisco Us Inc. Methods for improving multiple protein properties
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
KR20100075985A (ko) * 2007-10-31 2010-07-05 다니스코 유에스 인크. 세린 프로테아제가 없는 배경에서의 중성 메탈로프로테아제의 제조 및 용도
WO2009058956A1 (en) * 2007-11-01 2009-05-07 Danisco Us, Inc. Signal sequences and co-expressed chaperones for improving protein production in a host cell
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
EP2238164A1 (de) * 2008-01-29 2010-10-13 Danisco US Inc. Expression von streptomyces-subtilisin-inhibitor-(ssi-)proteinen in bacillus und streptomyces sp.
BRPI0908768A2 (pt) 2008-02-04 2015-07-28 Danisco Us Inc Variantes de olfa-amilase de ts23 com propriedades alteradas
RU2509776C2 (ru) * 2008-10-15 2014-03-20 ДАНИСКО ЮЭс ИНК. МОДИФИЦИРОВАННЫЕ ВАРИАНТЫ ИНГИБИТОРОВ ПРОТЕАЗ Bowman Birk
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20120172275A1 (en) 2009-03-10 2012-07-05 Danisco Us Inc. Bacillus Megaterium Strain DSM90-Related Alpha-Amylases, and Methods of Use, Thereof
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
BRPI1012590A2 (pt) 2009-04-08 2015-09-22 Danisco Us Inc Genencor Div alfa-amilases relacionadas à cepa wdg-195 de halomonas e métodos de uso das mesmas
CN105238801A (zh) 2009-04-24 2016-01-13 丹尼斯科美国公司 具有修饰的原区的蛋白酶
EP2424354A2 (de) * 2009-05-01 2012-03-07 Signal Investment & Management Co. Antimikrobielle befeuchtungszusammensetzung
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
GB0921001D0 (en) * 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
CA2782891C (en) 2009-12-09 2022-01-11 Danisco Us Inc. Compositions and methods comprising protease variants
EP2512501A4 (de) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr3-domänen
JP2013516427A (ja) * 2009-12-30 2013-05-13 ソレイ リミテッド ライアビリティ カンパニー 大豆加工ストリームから単離される精製ボーマン・バークプロテアーゼインヒビタープロテイン
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
ES2574056T3 (es) 2010-03-31 2016-06-14 Agency For Science, Technology And Research Péptido/peptoide anfifílico lineal e hidrogel que comprende el mismo
ES2625354T3 (es) 2010-04-15 2017-07-19 Danisco Us Inc. Composiciones y métodos que comprenden variantes de proteasas
ES2694398T3 (es) 2010-05-06 2018-12-20 Danisco Us Inc. Composiciones y métodos que comprenden variantes de subtilisina
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
RU2663114C2 (ru) 2011-05-05 2018-08-01 Дзе Проктер Энд Гэмбл Компани Способы и композиции, содержащие варианты сериновой протеазы
DK2705146T3 (en) 2011-05-05 2019-03-04 Danisco Us Inc COMPOSITIONS AND PROCEDURES INCLUDING SERINE PROTEASE VARIABLES
US20140187468A1 (en) 2011-08-31 2014-07-03 Danisco Us Inc. Compositions and Methods Comprising a Lipolytic Enzyme Variant
WO2013096653A1 (en) 2011-12-22 2013-06-27 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
CN104736700B (zh) 2012-10-12 2019-02-01 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
AU2013337255A1 (en) 2012-11-05 2015-04-02 Danisco Us Inc. Compositions and methods comprising thermolysin protease variants
WO2014100018A1 (en) 2012-12-19 2014-06-26 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
JP6367930B2 (ja) 2013-05-29 2018-08-01 ダニスコ・ユーエス・インク 新規メタロプロテアーゼ
WO2014194054A1 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
CN105492603B (zh) 2013-05-29 2022-06-03 丹尼斯科美国公司 新型金属蛋白酶
EP3004314B1 (de) 2013-05-29 2018-06-20 Danisco US Inc. Neuartige metalloproteasen
EP3022299B1 (de) 2013-07-19 2020-03-18 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
DK3044313T3 (da) 2013-09-12 2020-02-17 Danisco Us Inc Sammensætninger og fremgangsmåder omfattende lg12-clade- proteasevarianter
EP3055328A1 (de) * 2013-10-11 2016-08-17 F. Hoffmann-La Roche AG Nsp4-hemmer und verfahren zur verwendung
RU2016117275A (ru) 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
DK3080263T3 (da) 2013-12-13 2019-10-07 Danisco Us Inc Serinproteaser af bacillus gibsonii-clade
TR201906371T4 (tr) 2013-12-13 2019-05-21 Danisco Inc Bacillus türlerinin serin proteazları.
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
DK3119884T3 (da) 2014-03-21 2019-10-14 Danisco Us Inc Serinproteaser af bacillus-arter
US20170233710A1 (en) 2014-10-17 2017-08-17 Danisco Us Inc. Serine proteases of bacillus species
WO2016069548A2 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3212662B1 (de) 2014-10-27 2020-04-08 Danisco US Inc. Serinproteasen
EP3957729A1 (de) 2014-10-27 2022-02-23 Danisco US Inc. Serinproteasen
WO2016069544A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
WO2016069557A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases of bacillus species
CN107454914B (zh) 2015-03-12 2021-09-21 丹尼斯科美国公司 包含lg12进化枝蛋白酶变体的组合物和方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180112204A1 (en) 2015-05-13 2018-04-26 Danisco Us Inc. AprL-CLADE PROTEASE VARIANTS AND USES THEREOF
MX2017016499A (es) 2015-06-17 2018-03-12 Danisco Us Inc Proteasas con regiones de propeptido modificadas.
EP3310911B1 (de) 2015-06-17 2023-03-15 Danisco US Inc. Bacillus-gibboni-clade-serin-proteasen
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
BR112018072586A2 (pt) 2016-05-05 2019-02-19 Danisco Us Inc variantes de protease e usos das mesmas
US11661567B2 (en) 2016-05-31 2023-05-30 Danisco Us Inc. Protease variants and uses thereof
MX2018015559A (es) 2016-06-17 2019-06-06 Danisco Us Inc Variantes de proteasa y sus usos.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110312794B (zh) 2016-12-21 2024-04-12 丹尼斯科美国公司 吉氏芽孢杆菌进化枝丝氨酸蛋白酶
CN110312795B (zh) 2016-12-21 2024-07-23 丹尼斯科美国公司 蛋白酶变体及其用途
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
CN111373039A (zh) 2017-11-29 2020-07-03 丹尼斯科美国公司 具有改善的稳定性的枯草杆菌蛋白酶变体
US12415996B2 (en) 2018-06-19 2025-09-16 Danisco Us Inc. Subtilisin variants
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
EP3833731A1 (de) 2018-08-30 2021-06-16 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
WO2020088393A1 (zh) * 2018-10-31 2020-05-07 青岛蔚蓝生物集团有限公司 一种生产具有蛋白酶抗性的洗涤用酶的方法
EP3887515A1 (de) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
CN114174504A (zh) 2019-05-24 2022-03-11 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
WO2021146255A1 (en) 2020-01-13 2021-07-22 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
EP3872088A1 (de) * 2020-02-28 2021-09-01 Alganelle Verwendung von aprotinin als träger zum herstellen eines rekombinanten proteins, polypeptides oder peptids in algen
WO2022047149A1 (en) 2020-08-27 2022-03-03 Danisco Us Inc Enzymes and enzyme compositions for cleaning
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
EP4396320A2 (de) 2021-09-03 2024-07-10 Danisco US Inc. Waschmittelzusammensetzungen zum reinigen
EP4448750A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verwendungen davon
WO2023114794A1 (en) 2021-12-16 2023-06-22 The Procter & Gamble Company Fabric and home care composition comprising a protease
EP4448749A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
CN118679251A (zh) 2021-12-16 2024-09-20 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN118369414A (zh) 2021-12-16 2024-07-19 宝洁公司 包含蛋白酶的自动盘碟洗涤组合物
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
CA3265943A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. DETERGENT COMPOSITIONS AND ASSOCIATED PROCESSES
CN120112635A (zh) 2022-09-02 2025-06-06 丹尼斯科美国公司 枯草杆菌蛋白酶变体及其相关方法
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use
US20240263162A1 (en) 2023-02-01 2024-08-08 The Procter & Gamble Company Detergent compositions containing enzymes
EP4658776A1 (de) 2023-02-01 2025-12-10 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
WO2024186819A1 (en) 2023-03-06 2024-09-12 Danisco Us Inc. Subtilisin variants and methods of use
WO2025071996A1 (en) 2023-09-28 2025-04-03 Danisco Us Inc. Variant cutinase enzymes with improved solubility and uses thereof
WO2025085351A1 (en) 2023-10-20 2025-04-24 Danisco Us Inc. Subtilisin variants and methods of use
WO2026024922A1 (en) 2024-07-25 2026-01-29 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) * 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) * 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
WO1996016636A1 (en) 1994-11-28 1996-06-06 The Procter & Gamble Company Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents
CN1214082A (zh) * 1996-03-12 1999-04-14 金克克国际有限公司 碱性纤维素酶及其生产方法
EP0991422A1 (de) * 1996-04-18 2000-04-12 The General Hospital Corporation Modulierende interaktionen des epitheliums und des mesenchyms
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP0941057A1 (de) 1996-11-22 1999-09-15 The Procter & Gamble Company Kosmetische zusammensetzungen
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
EA003637B1 (ru) * 1998-07-20 2003-08-28 Инокселл А/С Новые способы идентификации биомолекул лигандов и мишеней
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
WO2000024371A1 (en) 1998-10-23 2000-05-04 The Procter & Gamble Company Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
WO2001072957A2 (en) * 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
ES2338097T3 (es) * 2000-04-14 2010-05-04 Genencor International, Inc. Procedimiento de identificacion selectiva.
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002002621A2 (en) * 2000-06-30 2002-01-10 Zymogenetics, Inc. Mammalian secreted proteins
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
JP4493271B2 (ja) * 2000-12-13 2010-06-30 アナフォア インコーポレイテッド Ｃ型レクチン様ドメインの骨格構造を有する蛋白質のコンビナトリアルライブラリ
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2002339119A1 (en) * 2001-02-07 2002-12-03 Centre National De La Recherche Scientifique (Cnrs) Sequence of the photorhabdus luminescens strain tt01 genome and uses
EP1592788A2 (de) * 2003-02-11 2005-11-09 Institut Pasteur Identifizierung und charakterisierung von racemasen, definition von protein-signaturen und tests für die identifizierung von d-aminosäuren und zum screenen von molekülen, die die aktivität von racemasen, insbesondere prolin-racemasen inhibieren
EP2292641B1 (de) * 2003-11-06 2017-12-06 Danisco US Inc. Expression in faserigen Pilzen von Proteasehemmern und Varianten davon
DE602004029812D1 (de) * 2003-11-06 2010-12-09 Danisco Us Inc Fgf-5-bindende und geträgerte peptide
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors

Also Published As

Publication number Publication date
US20080269139A1 (en) 2008-10-30
US20050203026A1 (en) 2005-09-15
WO2005047314A3 (en) 2006-04-20
US20110230405A1 (en) 2011-09-22
WO2005046709A2 (en) 2005-05-26
EP1680507A2 (de) 2006-07-19
WO2005047511A3 (en) 2005-11-24
US20080113917A1 (en) 2008-05-15
JP2008500805A (ja) 2008-01-17
EP1692159A2 (de) 2006-08-23
US7696173B2 (en) 2010-04-13
JP4843497B2 (ja) 2011-12-21
WO2005047511A2 (en) 2005-05-26
ES2375360T3 (es) 2012-02-29
US20050238607A1 (en) 2005-10-27
DK1680507T3 (da) 2011-10-10
EP1692158A2 (de) 2006-08-23
WO2005046710A3 (en) 2005-11-24
ATE513917T1 (de) 2011-07-15
EP1692159B1 (de) 2010-09-29
ATE486087T1 (de) 2010-11-15
US20050202535A1 (en) 2005-09-15
US7524816B2 (en) 2009-04-28
US20090111160A1 (en) 2009-04-30
WO2005046710A2 (en) 2005-05-26
US20130065829A1 (en) 2013-03-14
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
DE602004029393D1 (de) 2010-11-11
JP2012024091A (ja) 2012-02-09
EP1692160B1 (de) 2010-10-27
WO2005046709A3 (en) 2005-11-24
ATE530560T1 (de) 2011-11-15
EP1692160A2 (de) 2006-08-23
JP5728329B2 (ja) 2015-06-03
CA2544820C (en) 2014-02-18
ATE482972T1 (de) 2010-10-15
US7413877B2 (en) 2008-08-19
US7485618B2 (en) 2009-02-03
WO2005047314A2 (en) 2005-05-26
CA2544820A1 (en) 2005-05-26
EP1692158B1 (de) 2011-10-26

Similar Documents

Publication Publication Date Title
DE602004029812D1 (de) Fgf-5-bindende und geträgerte peptide
WO2006121610A3 (en) Personal care compositions and methods for their use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
ATE363531T1 (de) Claudin polypeptide
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение